Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Actionable Genome Consortium to guide NGS in cancer

Four major cancer institutes have joined Illumina to set up a program that helps oncologists diagnose, classify and treat cancer using next-generation sequencing. The Actionable Genome Consortium (AGC) brings together the San Diego–based sequencing giant with the Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center and Fred Hutchinson Cancer Research Center. The aim is to define genomic changes in patients' tumors that will allow oncologists to choose optimal therapies and testing strategies. The hope is that defining an 'actionable tumor' will support new diagnostics development and regulatory oversight for genomic testing in cancer.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Actionable Genome Consortium to guide NGS in cancer. Nat Biotechnol 32, 965 (2014).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing